Dow Jones
39.806,77 -196,82 (-0,49%) Nasdaq
16.794,88 +108,91 (+0,65%) Nikkei 225
39.019,73 -49,95 (-0,13%) EUR/USD
1,0861 0,0000 (-0,00%) Bitcoin EUR
65.499,05 +3.653,34 (+5,91%) CMC Crypto 200
1.522,31 +167,90 (+12,39%)
INCY May 2024 47.500 call
| Chiusura precedente | 4,1000 |
| Aperto | 5,8000 |
| Denaro | 7,4000 |
| Lettera | 11,6000 |
| Prezzo d'esercizio | 47,50 |
| Scadenza | 2024-05-17 |
| Min-Max giorno | 4,1000 - 5,8000 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 3 |
GlobeNewswireGlobal CAR T-cell Therapy Market Projected to Reach $83 Billion by 2032
PALM BEACH, Fla., Oct. 12, 2023 (GLOBE NEWSWIRE) -- FinancialNewsMedia.com News Commentary - Significant influences driving the CAR T-cell therapy market is a rising demand for model therapeutics for treatment of cancer, increase in prevalence of cancer and an escalating awareness of CAR T-cell therapy medicines. The CAR T-cell therapy market is currently going through a rapid expansion, owing to rapidly expanding clinical trial activities and recent commercialization of CAR-T cell therapy, whic
GlobeNewswireKnight Therapeutics Announces Regulatory Submission of Pemigatinib in Brazil
MONTREAL, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltd., has submitted a marketing authorization application for pemigatinib to ANVISA, the Brazilian health regulatory agency, under the rare diseases approval pathway, for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor recepto
